Ontology highlight
ABSTRACT:
PROVIDER: EGAO00000000362 | EGA |
REPOSITORIES: EGA
Gopalakrishnan V V Spencer C N CN Nezi L L Reuben A A Andrews M C MC Karpinets T V TV Prieto P A PA Vicente D D Hoffman K K Wei S C SC Cogdill A P AP Zhao L L Hudgens C W CW Hutchinson D S DS Manzo T T Petaccia de Macedo M M Cotechini T T Kumar T T Chen W S WS Reddy S M SM Szczepaniak Sloane R R Galloway-Pena J J Jiang H H Chen P L PL Shpall E J EJ Rezvani K K Alousi A M AM Chemaly R F RF Shelburne S S Vence L M LM Okhuysen P C PC Jensen V B VB Swennes A G AG McAllister F F Marcelo Riquelme Sanchez E E Zhang Y Y Le Chatelier E E Zitvogel L L Pons N N Austin-Breneman J L JL Haydu L E LE Burton E M EM Gardner J M JM Sirmans E E Hu J J Lazar A J AJ Tsujikawa T T Diab A A Tawbi H H Glitza I C IC Hwu W J WJ Patel S P SP Woodman S E SE Amaria R N RN Davies M A MA Gershenwald J E JE Hwu P P Lee J E JE Zhang J J Coussens L M LM Cooper Z A ZA Futreal P A PA Daniel C R CR Ajami N J NJ Petrosino J F JF Tetzlaff M T MT Sharma P P Allison J P JP Jenq R R RR Wargo J A JA
Science (New York, N.Y.) 20171102 6371
Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (<i>n</i> = 112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus nonresponders. Analysis of patien ...[more]